TATVA: Lower Revenue Outlook Will Weigh On Future Prospects

Narrative Update: Tatva Chintan Pharma Chem Analyst Price Target Revision Analysts have raised their fair value estimate for Tatva Chintan Pharma Chem from ₹865 to ₹1,035. This revision is based on improved profit margin expectations, which offset slightly reduced revenue growth projections and a marginally lower future P/E ratio.

Shared on 30 Jul 25

Fair value Increased 17%

The significant upward revision in Tatva Chintan Pharma Chem’s consensus price target reflects sharply improved net profit margins and a substantial reduction in forward P/E, supporting a new fair value estimate of ₹833.67. What's in the News Board meeting scheduled to consider and approve unaudited financial results for the quarter ended 30 June 2025.

Shared on 15 Jul 25

Fair value Decreased 35%

A sharp decline in net profit margin alongside a surge in future P/E indicates worsening profitability and a more expensive valuation, justifying the substantial reduction in Tatva Chintan Pharma Chem's fair value price target from ₹1139 to ₹742. WHAT'S IN THE NEWS Received an export order worth USD 3.56 million (INR 299.5 million) for Specialty Chemicals under the Pharma & Agro Intermediates & Speciality Chemicals category, to be delivered in Q3 FY26.